Cipla April-June Profit Rises 10%, Revenue Growth At 21-Quarter Low

Cipla Ltd. reported a 10% on-year rise in consolidated net profit for the April–June quarter at ₹12.98 billion, broadly in line with estimates, though it marked the lowest profit growth in 10 quarters. Revenue rose 4% on year to ₹69.57 billion, slightly below the forecast of ₹70.25 billion, and the slowest pace in 21 quarters. Shares rose 2.7% after the results.

The pharmaceuticals segment contributed ₹65.79 billion, up 3% on year, while revenue from new ventures rose 25% to ₹4.44 billion. EBITDA rose 4% on year to ₹17.78 billion with a margin of 25.6%, down 7 basis points.

Total expenses increased 4% on year to ₹54.46 billion, led by an 18% jump in material costs. R&D spend rose to ₹4.32 billion, or 6.2% of sales.

Domestic sales (One India) rose 6% to ₹30.70 billion, driven by growth in respiratory, cardiac, and urology therapies. Africa business grew 14% in rupee terms to ₹8.71 billion, while Europe and emerging markets rose 11% to ₹8.61 billion.

North America revenue declined 7% to ₹19.33 billion, but key products like Lanreotide gained market share. Cipla plans to launch 2–3 peptide assets in North America in 2025-26, with generics of Advair and Symbicort lined up through 2026-27.